Literature DB >> 9755864

The 26-mer peptide released from SNAP-25 cleavage by botulinum neurotoxin E inhibits vesicle docking.

A V Ferrer-Montiel1, L M Gutiérrez, J P Apland, J M Canaves, A Gil, S Viniegra, J A Biser, M Adler, M Montal.   

Abstract

Botulinum neurotoxin E (BoNT E) cleaves SNAP-25 at the C-terminal domain releasing a 26-mer peptide. This peptide product may act as an excitation-secretion uncoupling peptide (ESUP) to inhibit vesicle fusion and thus contribute to the efficacy of BoNT E in disabling neurosecretion. We have addressed this question using a synthetic 26-mer peptide which mimics the amino acid sequence of the naturally released peptide, and is hereafter denoted as ESUP E. This synthetic peptide is a potent inhibitor of Ca2+-evoked exocytosis in permeabilized chromaffin cells and reduces neurotransmitter release from identified cholinergic synapses in in vitro buccal ganglia of Aplysia californica. In chromaffin cells, both ESUP E and BoNT E abrogate the slow component of secretion without affecting the fast, Ca2+-mediated fusion event. Analysis of immunoprecipitates of the synaptic ternary complex involving SNAP-25, VAMP and syntaxin demonstrates that ESUP E interferes with the assembly of the docking complex. Thus, the efficacy of BoNTs as inhibitors of neurosecretion may arise from the synergistic action of cleaving the substrate and releasing peptide products that disable the fusion process by blocking specific steps of the exocytotic cascade.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9755864     DOI: 10.1016/s0014-5793(98)01012-6

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  9 in total

1.  The abscisic acid-related SNARE homolog NtSyr1 contributes to secretion and growth: evidence from competition with its cytosolic domain.

Authors:  Danny Geelen; Barbara Leyman; Henri Batoko; Gian-Pietro Di Sansebastiano; Ian Moore; Michael R Blatt; Gian-Pietro Di Sansabastiano
Journal:  Plant Cell       Date:  2002-02       Impact factor: 11.277

2.  Identification of SNARE complex modulators that inhibit exocytosis from an alpha-helix-constrained combinatorial library.

Authors:  Clara Blanes-Mira; Maria T Pastor; Elvira Valera; Gregorio Fernández-Ballester; Jaime M Merino; Luis M Gutierrez; Enrique Perez-Payá; Antonio Ferrer-Montiel
Journal:  Biochem J       Date:  2003-10-01       Impact factor: 3.857

Review 3.  Botulinum neurotoxin structure, engineering, and novel cellular trafficking and targeting.

Authors:  B R Singh
Journal:  Neurotox Res       Date:  2006-04       Impact factor: 3.911

4.  Persistence of Botulinum neurotoxin inactivation of nerve function.

Authors:  Charles B Shoemaker; George A Oyler
Journal:  Curr Top Microbiol Immunol       Date:  2013       Impact factor: 4.291

5.  Targeting botulinum neurotoxin persistence by the ubiquitin-proteasome system.

Authors:  Yien Che Tsai; Rhyan Maditz; Chueh-ling Kuo; Paul S Fishman; Charles B Shoemaker; George A Oyler; Allan M Weissman
Journal:  Proc Natl Acad Sci U S A       Date:  2010-09-07       Impact factor: 11.205

6.  Modulation of Kv2.1 channel gating and TEA sensitivity by distinct domains of SNAP-25.

Authors:  Yan He; Youhou Kang; Yuk-Man Leung; Fuzhen Xia; Xiaodong Gao; Huanli Xie; Herbert Y Gaisano; Robert G Tsushima
Journal:  Biochem J       Date:  2006-06-01       Impact factor: 3.857

Review 7.  Targeted secretion inhibitors-innovative protein therapeutics.

Authors:  Foster Keith; Chaddock John
Journal:  Toxins (Basel)       Date:  2010-12-03       Impact factor: 4.546

8.  Tyrosine phosphorylation of botulinum neurotoxin protease domains.

Authors:  Stephen Toth; Ernst E Brueggmann; George A Oyler; Leonard A Smith; Harry B Hines; S Ashraf Ahmed
Journal:  Front Pharmacol       Date:  2012-06-04       Impact factor: 5.810

9.  A mechanism for exocytotic arrest by the Complexin C-terminus.

Authors:  Mazen Makke; Madhurima Dhara; Dieter Bruns; Maria Mantero Martinez; Surya Gaya; Yvonne Schwarz; Walentina Frisch; Lina Silva-Bermudez; Martin Jung; Ralf Mohrmann
Journal:  Elife       Date:  2018-07-25       Impact factor: 8.140

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.